Table 2.
Potential Targets for New Drug Development
| Site of action | Effect | Reference |
|---|---|---|
| Transient receptor potential channel | Antagonist | 10, 59, 91, 106 |
| Cannabinoid receptor (CB1, CB2) | Agonist | 1, 4, 8, 13, 53, 65 |
| Potassium channels | Blocker | 52, 88 |
| Voltage-gated calcium channel | Blocker | 2, 12, 83 |
| Voltage-gated sodium channel | Blocker | 42, 110, 133 |
| Purinergic P2 receptor | Antagonist | 14, 23 |
| Nerve growth factor | Inhibitor | 57, 129 |
| Chemokine | Inhibitor | 47 |
| Proinflammatory Cytokine | Inhibitor | 107, 127 |
| Glutamate receptor | Antagonist | 45, 90 |
| Nicotinic acetylcholine receptor | Antagonist | 60 |
| Neurokinin receptor | Antagonist | 67 |
| Opioid/NMDA receptor antagonist | Combination | 131 |
| Catecholamine modulator | 45 | |
| Adenosine receptor | Agonist | 115 |